source
- Celltrion licenses Kaigene's preclinical antibody KG013 in deal worth up to $580.5 millionCelltrion, a South Korean biotech, has entered into a licensing agreement with Maryland-based Kaigene for a preclinical monoclonal antibody known as KG013. KG013 is designed to block the prolifera…
- Merck and Moderna’s cancer vaccine data leak precedes official Phase 3 results releaseResults from the Phase 3 trial of Moderna and Merck’s therapeutic cancer vaccine were made public on Thursday after an earlier leak of the data. The vaccine, called intismeran autogene, is being e…